TW307769B - - Google Patents

Download PDF

Info

Publication number
TW307769B
TW307769B TW082105942A TW82105942A TW307769B TW 307769 B TW307769 B TW 307769B TW 082105942 A TW082105942 A TW 082105942A TW 82105942 A TW82105942 A TW 82105942A TW 307769 B TW307769 B TW 307769B
Authority
TW
Taiwan
Prior art keywords
hydrochloride
patent application
water
crystalline hydrate
hydrate
Prior art date
Application number
TW082105942A
Other languages
English (en)
Chinese (zh)
Original Assignee
Shionogi & Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shionogi & Co filed Critical Shionogi & Co
Application granted granted Critical
Publication of TW307769B publication Critical patent/TW307769B/zh

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D501/00Heterocyclic compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Cephalosporin Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
TW082105942A 1992-07-31 1993-07-26 TW307769B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP20496592 1992-07-31

Publications (1)

Publication Number Publication Date
TW307769B true TW307769B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 1997-06-11

Family

ID=16499234

Family Applications (1)

Application Number Title Priority Date Filing Date
TW082105942A TW307769B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 1992-07-31 1993-07-26

Country Status (23)

Country Link
US (1) US5407929A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
EP (1) EP0581552B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
KR (1) KR100245938B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CN (1) CN1037683C (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AT (1) ATE165360T1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AU (1) AU657866B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
BR (1) BR9303235A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CA (1) CA2101502A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DE (1) DE69318077T2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ES (1) ES2115725T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
FI (1) FI933391L (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
GR (1) GR3026699T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
HU (1) HU219637B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
IL (1) IL106516A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
MX (1) MX9304611A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
NO (1) NO303734B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
NZ (1) NZ248285A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
PH (1) PH30109A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
PL (2) PL172830B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
RU (1) RU2118959C1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
TW (1) TW307769B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
UA (1) UA37181C2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ZA (1) ZA935529B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1368349E (pt) * 2001-02-24 2007-04-30 Boehringer Ingelheim Pharma Derivados de xantina, sua preparação e sua utilização como medicamento
AT413282B (de) * 2002-02-01 2006-01-15 Sandoz Ag Kristalline salze der 7-(((5-amino-1,2,4-thiadiazol-3-yl) (fluoromethoxy-imino)acetyl)amino)-3- ((imino-1-piperazinylmethyl)
KR20030076759A (ko) * 2002-03-21 2003-09-29 주식회사 엘지생명과학 신규 세팔로스포린 화합물 및 그의 제조 방법
US7407955B2 (en) 2002-08-21 2008-08-05 Boehringer Ingelheim Pharma Gmbh & Co., Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
US6727277B1 (en) 2002-11-12 2004-04-27 Kansas State University Research Foundation Compounds affecting cholesterol absorption
JP5192147B2 (ja) 2003-02-12 2013-05-08 日産化学工業株式会社 ピタバスタチンカルシウムの結晶質形態
BRPI0408716B1 (pt) 2003-03-27 2017-08-29 Basilea Pharmaceutica Ag. Cefalosporin in crystalline form, process for its preparation and its uses, and preparation of cephalosporin
US7501426B2 (en) * 2004-02-18 2009-03-10 Boehringer Ingelheim International Gmbh 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions
DE102004054054A1 (de) 2004-11-05 2006-05-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine
DE102005035891A1 (de) * 2005-07-30 2007-02-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg 8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
MX2008014024A (es) 2006-05-04 2008-11-14 Boehringer Ingelheim Int Formas poliformas.
PE20110235A1 (es) * 2006-05-04 2011-04-14 Boehringer Ingelheim Int Combinaciones farmaceuticas que comprenden linagliptina y metmorfina
EP1852108A1 (en) 2006-05-04 2007-11-07 Boehringer Ingelheim Pharma GmbH & Co.KG DPP IV inhibitor formulations
ES2733348T3 (es) * 2007-08-17 2019-11-28 Boehringer Ingelheim Int Derivados de purina para uso en el tratamiento de enfermedades relacionadas con FAP
PE20140960A1 (es) 2008-04-03 2014-08-15 Boehringer Ingelheim Int Formulaciones que comprenden un inhibidor de dpp4
PE20100156A1 (es) * 2008-06-03 2010-02-23 Boehringer Ingelheim Int Tratamiento de nafld
UY32030A (es) 2008-08-06 2010-03-26 Boehringer Ingelheim Int "tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
BRPI0916997A2 (pt) 2008-08-06 2020-12-15 Boehringer Ingelheim International Gmbh Inibidor de dpp-4 e seu uso
EP2326326B1 (en) * 2008-08-15 2019-10-09 Boehringer Ingelheim International GmbH Dpp-4 inhibitors for use for the treatment of wound healing in diabetic patients
WO2010029089A2 (en) 2008-09-10 2010-03-18 Boehringer Ingelheim International Gmbh Combination therapy for the treatment of diabetes and related conditions
US20200155558A1 (en) 2018-11-20 2020-05-21 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
EP2382216A1 (en) 2008-12-23 2011-11-02 Boehringer Ingelheim International GmbH Salt forms of organic compound
AR074990A1 (es) 2009-01-07 2011-03-02 Boehringer Ingelheim Int Tratamiento de diabetes en pacientes con un control glucemico inadecuado a pesar de la terapia con metformina
EP2504002B1 (en) 2009-11-27 2019-10-09 Boehringer Ingelheim International GmbH Treatment of genotyped diabetic patients with dpp-iv inhibitors such as linagliptin
PT2566469T (pt) 2010-05-05 2023-01-10 Boehringer Ingelheim Int Terapia de combinação
JP5843855B2 (ja) 2010-06-24 2016-01-13 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 糖尿病療法
AR083878A1 (es) 2010-11-15 2013-03-27 Boehringer Ingelheim Int Terapia antidiabetica vasoprotectora y cardioprotectora, linagliptina, metodo de tratamiento
DK2731947T3 (en) 2011-07-15 2019-04-23 Boehringer Ingelheim Int SUBSTITUTED DIMERIC QUINAZOLINE DERIVATIVE, PREPARATION AND USE thereof IN PHARMACEUTICAL COMPOSITIONS FOR TREATMENT OF TYPE I AND TYPE II DIABETES
US9555001B2 (en) 2012-03-07 2017-01-31 Boehringer Ingelheim International Gmbh Pharmaceutical composition and uses thereof
WO2013171167A1 (en) 2012-05-14 2013-11-21 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp -4 inhibitor for use in the treatment of podocytes related disorders and/or nephrotic syndrome
EP2849754B1 (en) 2012-05-14 2022-09-14 Boehringer Ingelheim International GmbH Linagliptin, a xanthine derivative as dpp-4 inhibitor, for use in the treatment of sirs and/or sepsis
WO2013174767A1 (en) 2012-05-24 2013-11-28 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
WO2015128453A1 (en) 2014-02-28 2015-09-03 Boehringer Ingelheim International Gmbh Medical use of a dpp-4 inhibitor
CN109310697A (zh) 2016-06-10 2019-02-05 勃林格殷格翰国际有限公司 利格列汀和二甲双胍的组合

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES475573A1 (es) * 1977-07-12 1980-01-16 Fujisawa Pharmaceutical Co Un procedimiento para preparar nuevos compuestos de cefem
IE65926B1 (en) * 1990-07-19 1995-11-29 Shionogi & Co Thioalkylthio cephalosporin derivatives

Also Published As

Publication number Publication date
IL106516A0 (en) 1993-11-15
DE69318077T2 (de) 1998-10-29
AU4422793A (en) 1994-02-03
GR3026699T3 (en) 1998-07-31
EP0581552B1 (en) 1998-04-22
CN1037683C (zh) 1998-03-11
HU9302194D0 (en) 1993-10-28
EP0581552A2 (en) 1994-02-02
IL106516A (en) 1998-06-15
CA2101502A1 (en) 1994-02-01
HUT68602A (en) 1995-06-28
EP0581552A3 (en) 1994-06-01
FI933391A0 (fi) 1993-07-29
FI933391A7 (fi) 1994-02-01
UA37181C2 (uk) 2001-05-15
ZA935529B (en) 1994-02-24
RU2118959C1 (ru) 1998-09-20
ATE165360T1 (de) 1998-05-15
AU657866B2 (en) 1995-03-23
FI933391L (fi) 1994-02-01
PL299870A1 (en) 1994-02-07
PH30109A (en) 1996-12-27
NO303734B1 (no) 1998-08-24
PL172830B1 (pl) 1997-12-31
US5407929A (en) 1995-04-18
PL172835B1 (pl) 1997-12-31
CN1089948A (zh) 1994-07-27
NZ248285A (en) 1994-07-26
DE69318077D1 (de) 1998-05-28
BR9303235A (pt) 1994-03-01
ES2115725T3 (es) 1998-07-01
HU219637B (hu) 2001-06-28
KR100245938B1 (ko) 2000-04-01
MX9304611A (es) 1994-02-28
NO932745L (no) 1994-02-01
KR940005636A (ko) 1994-03-22
NO932745D0 (no) 1993-07-30

Similar Documents

Publication Publication Date Title
TW307769B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
RU2186778C2 (ru) Натриевая соль омепразола формы б, способ ее получения (варианты) и фармацевтический препарат, содержащий натриевую соль омепразола формы б
SA97180739B1 (ar) الشكل البللوري للمتشاكل S - enantiomer للأومبرازول omeprazole
JPH0255437B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
NL192266C (nl) Werkwijze voor het bereiden van een kristallijn cefepime-dihydrochloride alsmede het kristallijne dihydrochloride en mengsels die het bevatten.
JP2009143957A (ja) アトルバスタチンヘミカルシウム溶媒和物の脱溶媒和法及び有機溶媒を本質的に含まないアトルバスタチンヘミカルシウム
ES2390611T3 (es) Agente de erradicación de Helicobacter pylori que tiene actividad inhibidora sobre la secreción de ácido gástrico
TWI293631B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DK163514B (da) Fremgangsmaade til fremstilling af en krystallinsk form af natriumsaltet af et oximderivat af 7-aminothiazolylacetamidocephalosporansyre
SE449996B (sv) (6r,7r)-7-/(z)-2-(2-aminotiazol-4-yl)-2-(2-karboxiprop-2-oxiimino)acetamidol/-3-(1-pyridiniummetyl)cef-3-em-4-karboxylat i form av en kristallin bishydroklorid farmaceutisk komposition derav samt anvendning som mellanpr
JPS62294615A (ja) 抗菌剤
JP2575590B2 (ja) トリアゾリルチオメチルチオセファロスポリン塩酸塩およびその水和物結晶ならびにそれらの製法
JPH0741484A (ja) セフェム化合物及び抗菌剤
CA2082472A1 (en) Crystalline form of a cephalosporin antibiotic
FR2884822A1 (fr) Derives de triazines, leur preparation et leur application en therapeutique
HU204271B (en) Process for producing cristalline 1-carba-dethia-cepheme-solvates
US10717729B2 (en) Thiamine-organic acid salt
SU973024A3 (ru) Способ получени аддитивных солей пивалоилоксиметилового эфира 7 @ -[2-(2-аминотиазол-4-ил) ацетамидо]-3-[1-(2-диметиламиноэтил)-1н-тетразол-5-илтиометил]-3-цефем-4-карбоновой кислоты с сол ной,винной или лимонной кислотой
FR2952M (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
RU2785195C1 (ru) Способ получения полиморфной формы 4-(3-этокси-4-гидроксибензил)-N-(2,4-дифторфенил)-5-оксо-5,6-дигидро-4H-1,3,4-тиадиазин-2-карбоксамида
US20110118462A1 (en) N-heterocyclic substituent-containing antibiotic, preparation and use thereof
US3682953A (en) Substituted 5-nitrofuryl-pyrazoles
JPH04234880A (ja) β−ラクタム抗生物質の結晶性塩酸塩
US3835165A (en) Nitrofuryl-alpha-halo-hydrazones
WO2017142002A1 (ja) C-4"位置換マクロライド化合物フリー体及び塩の結晶形並びにそれらの製造方法